Minister: GPs are not precluded from prescribing OTC medicines, but should follow guidance

Minister: GPs are not precluded from prescribing OTC medicines, but should follow guidance

April 20 2018 Doctors have not been prevented from prescribing over-the counter medicines, but...

CPPE announces new Patient Safety Focal Point events and invites Seacole applications

CPPE announces new Patient Safety Focal Point events and invites Seacole applications

April 20 2018 An anticoagulant case study is the theme of the latest Patient Safety Focal Point...

RPS hustings transcript available online

RPS hustings transcript available online

April 19 2018The transcript of the online hustings for this year’s elections to Royal...

NICE issues guidance on Lyme disease

NICE issues guidance on Lyme disease

April 13 2018 NICE has issued new guidance on Lyme disease to raise awareness among health...

MHRA announces success in cutting diversion of benzos and Z drugs to black market

MHRA announces success in cutting diversion of benzos and Z drugs to black market

April 13 2018 A crack-down on the diversion of Prescription Only Medicines onto the black market...

  • Minister: GPs are not precluded from prescribing OTC medicines, but should follow guidance

    Minister: GPs are not precluded from prescribing OTC medicines, but should follow guidance

    Friday, 20 April 2018 16:25
  • CPPE announces new Patient Safety Focal Point events and invites Seacole applications

    CPPE announces new Patient Safety Focal Point events and invites Seacole applications

    Friday, 20 April 2018 16:13
  • RPS hustings transcript available online

    RPS hustings transcript available online

    Thursday, 19 April 2018 16:28
  • NICE issues guidance on Lyme disease

    NICE issues guidance on Lyme disease

    Friday, 13 April 2018 09:19
  • MHRA announces success in cutting diversion of benzos and Z drugs to black market

    MHRA announces success in cutting diversion of benzos and Z drugs to black market

    Friday, 13 April 2018 09:23

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageJanuary 10 2018

The medicines regulator has highlighted the different strengths of co-dydramol in its latest Drug Safety Update. 

For many years co-dydramol has been available at a fixed ratio of 1:50, combining dihydrocodeine 10mg and paracetamol 500mg. However, the MHRA’s latest DSU is advising that new strengths containing greater amounts of dihydrocodeine – co-dydramol 20/500 mg and co-dydramol 30/500 mg tablets – are becoming available.

Health professionals should take care to ensure the intended strength is clearly prescribed and the correct strength is dispensed, says the MHRA. If the prescribed strength is unclear, the person dispensing should contact the prescriber for clarification. It is also asking that health professionals “report suspected adverse drug reactions with opioids, including any harm from medication error, via the Yellow Card Scheme.”

The January 6 DSU newsletter also asks health professionals to ask if a patient has been using herbal medicines when reporting any suspected adverse drug reaction. If herbal medicines or traditional Chinese medicines have been used, this information should be included on the Yellow Card scheme report.

Ideally, information about a herbal product should include the brand name, the list of ingredients, a copy of the package labelling if available, and any manufacturer details. Patients should also be advised to check for the Traditional Herbal Registration Certification Mark.

Another medicine included in the DSU newsletter is daclizumab (daclizumab beta), which is “now restricted to adults with relapsing multiple sclerosis who have had an inadequate response to at least two other disease-modifying therapies (DMTs) and for whom other DMTs are contraindicated or unsuitable.”

The MHRA is advising that patients with pre-existing hepatic disease or hepatic impairment should not use daclizumab. Caution should also be taken in prescribing daclizumab “in patients receiving other medication that may be hepatotoxic, including over-the-counter products and herbal medicines.”

Links:
MHRA Drug Safety Update: monthly PDF newsletters        
MHRA Drug Safety Update: monthly PDF newsletter. January 6 2018. 11;6.                 
Co-dydramol DSU             
Herbal medicines DSU    
Daclizumab DSU                

Practice News

April 20 2018 Doctors have not been prevented from prescribing over-the counter medicines, but should use proper clinical judgement, a health minister has said.
April 20 2018 Doctors have not been prevented from prescribing over-the counter medicines, but should use proper clinical judgement, a health minister has said. A question was raised following last...